23rd Invitation to Manufacturers and Suppliers of Medicinal Products for HIV Infections and Related Diseases to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit

The 23rd EOI for HIV/AIDS Products includes the addition of a co-pack of Cabotegravir extended-release intramuscular injection + Rilpivirine extended release intramuscular injection, as well as the addition of the antibiotic Benzathine benzylpenicillin powder for intramuscular injection. Further, several FDC products containing Tenofovir alafenamide (TAF) have been redesignated as priority products for WHO PQT/MED.